[Bacteriological and pharmacological properties of new cephalosperine antibiotics. II. Cephaloridine].
D000667:Ampicillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002509:Cephaloridine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000633:toxicity / Q000652:urine; D002512:Cephalothin / Q000494:pharmacology; D004009:Dicloxacillin / Q000494:pharmacology; D004355:Drug Stability; D004361:Drug Tolerance; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D010068:Oxacillin / Q000494:pharmacology; D010400:Penicillin G / Q000494:pharmacology; D010403:Penicillin Resistance; D011485:Protein Binding; D011511:Proteus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012475:Salmonella / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000667:Ampicillin; D004009:Dicloxacillin; D002509:Cephaloridine; D010400:Penicillin G; D002512:Cephalothin; D010068:Oxacillin
Bakteriologische und pharmakologische Eigenschaften der neuen Cephalosporin-Antibiotica.